| Product Code: ETC067180 | Publication Date: Jun 2021 | Updated Date: Jun 2026 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The China Liquid Biopsy Market was estimated at USD 151 Million in 2025 and is projected to reach USD 175 Million by 2032, growing at a CAGR of 2.1% from 2026 to 2032. This positive trajectory is primarily driven by the rising cancer prevalence within the country, alongside substantial advancements in healthcare infrastructure. Furthermore, increasing awareness among patients and healthcare providers regarding the benefits of early cancer detection is set to enhance the adoption of liquid biopsy technologies.
This graph highlights how the China Liquid Biopsy Market has steadily grown over the years, supported by major growth factors.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate | Major Drivers |
| 2021 | -3.5% | Rising electricity demand across industries |
| 2022 | 6.3% | Increasing smart city development projects |
| 2023 | -1.9% | Increasing industrial automation investments |
| 2024 | 4.4% | Expansion of transportation and logistics networks |
| 2025 | 3.0% | Increasing industrial infrastructure investments |
| 2026 | 4.6% | Increasing smart city development projects |
| 2027 | 2.7% | Growing urbanization and commercial development |
| 2028 | 3.2% | Increasing smart city development projects |
| 2029 | 2.9% | Growing renewable energy integration projects |
| 2030 | 3.0% | Expansion of commercial construction activities |
| 2031 | 2.9% | Increasing adoption of advanced technologies |
| 2032 | 2.9% | Increasing industrial infrastructure investments |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch’s advanced forecasting approach, validated with industry datasets as of June 2026.
A growing demand for non-invasive cancer diagnostic methods is a significant factor propelling the China liquid biopsy market. The popularity of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) is indicative of a shift in preference towards techniques that minimize patient discomfort while providing essential diagnostic information.
As healthcare providers increasingly adopt liquid biopsy technologies for real-time monitoring of tumor progression, the market is witnessing innovations aimed at enhancing the sensitivity and specificity of these tests. Collaborations between academic institutions and industry players are crucial in driving this innovation and expediting the development of cutting-edge solutions.
Despite the promising growth outlook, the China liquid biopsy market faces significant restraints that could impede its full potential. One of the primary challenges is the lack of standardized regulations and guidelines, which affects the accuracy, reliability, and consistency of liquid biopsy tests. Additionally, concerns surrounding data privacy, as well as sample collection and storage standards, must be addressed to foster trust among patients and healthcare providers. Competing diagnostic technologies, particularly traditional tissue biopsies, also pose a challenge, requiring liquid biopsy solutions to demonstrate clear advantages in clinical utility and cost-effectiveness.
Several key trends are shaping the future of the China liquid biopsy market. The development of advanced technologies like extracellular vesicles (EVs) is gaining traction for their potential in early cancer detection and treatment monitoring. Furthermore, an increasing focus on personalized medicine is driving healthcare providers to embrace liquid biopsies for tailored treatment plans.
The emergence of multi-cancer early detection tests and expanded product portfolios is also noteworthy, as companies aim to cater to various cancer types. Such innovations are expected to foster greater acceptance and utilization of liquid biopsy tests among both clinicians and patients.
The China Liquid Biopsy Market is ripe for investment, particularly in companies dedicated to developing innovative testing kits and platforms. The increasing demand for non-invasive testing methods presents a unique opportunity for stakeholders to capture market share. Collaborating with healthcare institutions and research centers is another strategic avenue for growth, allowing for the acceleration of product development and commercialization in this fast-evolving landscape.
The Chinese government has proactively implemented various policies to encourage the growth of the liquid biopsy market. Guidelines established by the National Health Commission aim to standardize the development and application of these technologies for cancer diagnosis and treatment. Additionally, funding support for research and development initiatives, along with the establishment of approval processes by regulatory bodies like the China Food and Drug Administration (CFDA), are all designed to enhance safety and efficacy in the sector.
Looking ahead to 2026-2032, the China liquid biopsy market is poised for continued growth as the prevalence of cancer rises and the adoption of precision medicine becomes more widespread. The capability for non-invasive and real-time monitoring of tumor dynamics positions liquid biopsies as a crucial tool in personalized cancer care. With an increasing demand for early detection and effective treatment monitoring, the market will likely expand, driven by innovative collaborations and technological advancements.
In recent months, the industry has seen various developments aimed at enhancing the precision and utility of liquid biopsy technologies. Research initiatives have intensified, focusing on integrating artificial intelligence and machine learning to refine test accuracy and streamline data analysis. Collaborative efforts between biotech firms and research institutions are yielding promising results, with several new testing platforms entering the pipeline, aimed at improving the clinical applicability of liquid biopsies.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Liquid Biopsy Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Liquid Biopsy Market Revenues & Volume, 2022 & 2032F |
3.3 China Liquid Biopsy Market - Industry Life Cycle |
3.4 China Liquid Biopsy Market - Porter's Five Forces |
3.5 China Liquid Biopsy Market Revenues & Volume Share, By Form, 2022 & 2032F |
3.6 China Liquid Biopsy Market Revenues & Volume Share, By Form, 2022 & 2032F |
3.7 China Liquid Biopsy Market Revenues & Volume Share, By End User, 2022 & 2032F |
4 China Liquid Biopsy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in China |
4.2.2 Growing awareness and adoption of liquid biopsy as a non-invasive diagnostic tool |
4.2.3 Rising investments in healthcare infrastructure and research development |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for liquid biopsy products in China |
4.3.2 Limited reimbursement policies for liquid biopsy tests |
4.3.3 High cost associated with liquid biopsy procedures |
5 China Liquid Biopsy Market Trends |
6 China Liquid Biopsy Market, By Types |
6.1 China Liquid Biopsy Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 China Liquid Biopsy Market Revenues & Volume, By Product, 2022-2032F |
6.1.3 China Liquid Biopsy Market Revenues & Volume, By Handheld Instruments, 2022-2032F |
6.1.4 China Liquid Biopsy Market Revenues & Volume, By Inflation Devices, 2022-2032F |
6.1.5 China Liquid Biopsy Market Revenues & Volume, By Guiding Devices, 2022-2032F |
6.1.6 China Liquid Biopsy Market Revenues & Volume, By Electrosurgical & Electrocautery Instruments, 2022-2032F |
6.1.7 China Liquid Biopsy Market Revenues & Volume, By Others, 2022-2032F |
6.2 China Liquid Biopsy Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 China Liquid Biopsy Market Revenues & Volume, By Clinical Application, 2022-2032F |
6.2.3 China Liquid Biopsy Market Revenues & Volume, By Non-clinical Application, 2022-2032F |
6.3 China Liquid Biopsy Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 China Liquid Biopsy Market Revenues & Volume, By Hospitals, 2022-2032F |
6.3.3 China Liquid Biopsy Market Revenues & Volume, By Academic & Research Centers, 2022-2032F |
6.3.4 China Liquid Biopsy Market Revenues & Volume, By Others, 2022-2032F |
7 China Liquid Biopsy Market Import-Export Trade Statistics |
7.1 China Liquid Biopsy Market Export to Major Countries |
7.2 China Liquid Biopsy Market Imports from Major Countries |
8 China Liquid Biopsy Market Key Performance Indicators |
8.1 Adoption rate of liquid biopsy tests by healthcare providers in China |
8.2 Number of research studies and publications on liquid biopsy in China |
8.3 Investments in liquid biopsy technology and companies in China |
9 China Liquid Biopsy Market - Opportunity Assessment |
9.1 China Liquid Biopsy Market Opportunity Assessment, By Product, 2022 & 2032F |
9.2 China Liquid Biopsy Market Opportunity Assessment, By Application, 2022 & 2032F |
9.3 China Liquid Biopsy Market Opportunity Assessment, By End User, 2022 & 2032F |
10 China Liquid Biopsy Market - Competitive Landscape |
10.1 China Liquid Biopsy Market Revenue Share, By Companies, 2025 |
10.2 China Liquid Biopsy Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here